AMRUTANJAN
Amrutanjan Health Care Limited
Each stock's 10,000-path forecast, rendered as light.
Amrutanjan Health Care Limited (AMRUTANJAN) Stock Analysis & Case Study
Is AMRUTANJAN a good buy? The data-driven verdict.
Amrutanjan Health Care Limited (AMRUTANJAN) trades at ₹521,on the numbers it mixed signals, a Downstox Snapshot Score of 52/100.
On the numbers, Amrutanjan Health Care Limited (AMRUTANJAN) mixed signals, a Downstox Snapshot Score of 52/100, weighing expensive at 74.0× earnings, ROE of 20.0%, a 59% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
AMRUTANJAN fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How AMRUTANJAN ranks against the 2,373 companies in our screener
- AMRUTANJAN's market cap of 1,507 Cr ranks in the 46th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AMRUTANJAN's book value of ₹37 ranks in the 27th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AMRUTANJAN's promoter holding of 46.5% ranks in the 25th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AMRUTANJAN's 3-year profit (PAT) growth of 27.0% ranks in the 66th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AMRUTANJAN's 3-year revenue growth of 11.0% ranks in the 53rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AMRUTANJAN's debt-to-equity ratio of 0.02x is lower than 94% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is AMRUTANJAN overvalued? AMRUTANJAN P/E vs peers
AMRUTANJAN trades at 74.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
AMRUTANJAN share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of AMRUTANJAN history (8%/yr drift, 29%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| AMRUTANJAN 2027 | ₹383 | ₹559 | ₹815 | +7% |
| AMRUTANJAN 2028 | ₹356 | ₹598 | ₹1,005 | +15% |
| AMRUTANJAN 2029 | ₹338 | ₹641 | ₹1,217 | +23% |
| AMRUTANJAN 2030 | ₹327 | ₹687 | ₹1,441 | +32% |
| AMRUTANJAN 2031 | ₹320 | ₹736 | ₹1,694 | +41% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability AMRUTANJAN goes up, or doubles?
The bull case for AMRUTANJAN
- AMRUTANJAN's return on equity of 20.0% ranks in the 84th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AMRUTANJAN's return on capital employed of 31.4% ranks in the 93rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,217.
The bear case & risks
- AMRUTANJAN's P/E of 74.0x is lower than 16% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 14.0× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹338.
AMRUTANJAN volatility & expected range, how bumpy is the ride?
Over the last 9.8 years AMRUTANJAN compounded at 8%/year with annualized volatility of 29%. That volatility implies a 1-year 80% range of ₹383-₹815, the honest backbone behind any single price target.
AMRUTANJAN price forecast, the full 60-month probability fan
AMRUTANJAN price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds AMRUTANJAN hits common targets within the simulated horizon?
Full multi-horizon detail on the AMRUTANJAN price target & forecast page.
AMRUTANJAN Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. AMRUTANJAN scores 6/8, mixed financial health.
AMRUTANJAN MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy AMRUTANJAN with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 50.00% | 2.0× |
| Groww | 28.65% | 3.5× |
| Dhan | 40.00% | 2.5× |
| Kotak Neo | 100.00% | 1.0× |
| Paytm Money | 28.57% | 3.5× |
| Pocketful | 50.00% | 2.0× |
| Anand RathiCHEAPEST | 28.55% | 3.5× |
| Bajaj Broking | 35.00% | 2.9× |
| Share India | 28.64% | 3.5× |
Compare every broker on the AMRUTANJAN MTF page.
About Amrutanjan Health Care Limited: sector, index & market-cap context
Amrutanjan Health Care Limited (AMRUTANJAN) is a small-cap NSE-listed company, with a market capitalisation of ₹1,507 Cr. See more stocks on our screener.
How the AMRUTANJAN Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Amrutanjan Health Care Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
AMRUTANJAN analysis, FAQs
Is Amrutanjan Health Care Limited (AMRUTANJAN) a good buy?
On the numbers, Amrutanjan Health Care Limited (AMRUTANJAN) mixed signals, a Downstox Snapshot Score of 52/100, weighing expensive at 74.0× earnings, ROE of 20.0%, a 59% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is AMRUTANJAN overvalued or undervalued?
AMRUTANJAN trades at 74.0× earnings, expensive versus the ~22× long-run Nifty average.
What is the AMRUTANJAN share price target for 2031?
AMRUTANJAN's probability-weighted 2031 median target is ₹736, with an 80% range of ₹320-₹1,694 (10,000-path Monte-Carlo).
What is the probability AMRUTANJAN doubles in 5 years?
The modelled probability of AMRUTANJAN reaching ₹1,043 (2×) within 5 years is 30%.
What is the bull case for AMRUTANJAN?
AMRUTANJAN's return on equity of 20.0% ranks in the 84th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. AMRUTANJAN's return on capital employed of 31.4% ranks in the 93rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in AMRUTANJAN?
AMRUTANJAN's P/E of 74.0x is lower than 16% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 14.0× price-to-book means most of the value is intangible/expectations, not assets on the books.